Top

Journal of Radiation Oncology

Published in:

01-06-2012 | Original Research

Stereotactic body radiotherapy for adrenal metastases from lung cancer

Authors: Michael Guiou, Nina A. Mayr, Edward Y. Kim, Terence Williams, Simon S. Lo

Published in: Journal of Radiation Oncology | Issue 2/2012

Abstract

Purpose

The adrenal glands are common sites of metastatic disease in lung cancer and can be highly symptomatic. Current treatment approaches for adrenal oligometastases, including surgical resection and chemoembolization, are invasive and can be associated with considerable morbidity. More recently, stereotactic body radiotherapy (SBRT) has shown promising tumor control rates in primary lung cancer and oligometastases of various sites, but relatively less data exist on the efficacy of SBRT for adrenal metastases. The purpose of this study is to assess tumor regression pattern, local control, overall survival, pain relief, and treatment morbidity in patients treated with SBRT for adrenal metastases from lung cancer.

Methods and materials

Eleven lesions were treated with SBRT in nine patients with lung cancer and followed with post-therapy clinical exams and computed tomography. Response Evaluation Criteria in Solid Tumors (RECIST)-based tumor response was assessed and volumetric tumor measurements were obtained by serial three-dimensional contouring. Symptomatic control, overall survival, and radiation therapy-associated side effects were assessed at follow-up visits. Mean post-therapy follow-up was 7.3 months.

Results

The prescribed dose ranged from 20.0 to 37.5 Gy in five fractions (mean, 24.9 ± 7.6 Gy), corresponding to a BED₁₀ of 28.0 to 65.6 (mean, 41.6 ± 11.6) Gy. Overall RECIST-based response rate was 67%; 1-year and 2-year local control was 44%; and 1-year and 2-year overall survival were 52% and 13%, respectively. Volumetric response was much more rapid in small cell than in non-small cell carcinomas (slope, −31.0% vs. −5.9%/month, respectively, p = 0.06). Patients with metachronous lesions had longer survival (1 year, 60%; 2 year, 20%) than patients with synchronous lesions (1 year, 38%; 2 year, 0%). No early or late grade ≤ 3 adverse effects occurred.

Conclusion

SBRT is a useful non-invasive treatment option for adrenal metastases from lung cancer, providing good local control with minimal morbidity. Small cell carcinoma lesions show rapid response that may require adaptive re-planning.

Katoh N, Onimaru R, Sakuhara Y, Abo D, Shimizu S, Taguchi H, Watanabe Y, Shinohara N, Ishikawa M, Shirato H (2008) Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother Oncol 87(3):418–424PubMedCrossRef

Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, Milano MT (2009) Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 75(1):71–75PubMedCrossRef

Holy R, Piroth M, Pinkawa M, Eble MJ (2011) Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 187(4):245–251PubMedCrossRef

Torok J, Wegner RE, Burton SA, Heron DE (2011) Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol 7(1):145–151PubMedCrossRef

Casamassima F, Livi L, Masciullo S, Menichelli C, Masi L, Meattini I, Bonucci I, Agresti B, Simontacchi G, Doro R (2012) Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. Int J Radiat Oncol Biol Phys 82(2):919–923PubMedCrossRef

Raz DJ, Lanuti M, Gaissert HC, Wright CD, Mathisen DJ, Wain JC (2011) Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. Ann Thorac Surg 92(5):1788–1792, discussion 1793PubMedCrossRef

Sancho, JJ, F Triponez, X Montet, and A Sitges-Serra (2011) Surgical management of adrenal metastases. Langenbecks Arch Surg 397:179-194

Paul CA, Virgo KS, Wade TP, Audisio RA, Johnson FE (2000) Adrenalectomy for isolated adrenal metastases from non-adrenal cancer. Int J Oncol 17(1):181–187PubMed

Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Hoss A, Schlegel W, Wannenmacher MF (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19(1):164–170PubMed

10.

Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M (2004) Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60(1):186–196PubMedCrossRef

11.

Gerszten PC, Burton SA, Belani CP, Ramalingam S, Friedland DM, Ozhasoglu C, Quinn AE, McCue KJ, Welch WC (2006) Radiosurgery for the treatment of spinal lung metastases. Cancer 107(11):2653–2661PubMedCrossRef

12.

Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 45(7):831–837PubMedCrossRef

13.

Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros L, Schell MC (2006) Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol 45(7):808–817PubMedCrossRef

14.

Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, Flentje M (2006) Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 45(7):838–847PubMedCrossRef

15.

Gerszten PC, Burton SA, Ozhasoglu C, Welch WC (2007) Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 32(2):193–199CrossRef

16.

Hof H, Hoess A, Oetzel D, Debus J, Herfarth K (2007) Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol 183(12):673–678PubMedCrossRef

17.

Vautravers-Dewas C, Dewas S, Bonodeau F, Adenis A, Lacornerie T, Penel N, Lartigau E, Mirabel X (2011) Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys 81(3):e39–e47PubMedCrossRef

18.

Lo SS, Teh BS, Mayr NA, Olencki TE, Wang JZ, Grecula JC, Lu JJ, Timmerman RD (2010) Stereotactic body radiation therapy for oligometastases. Discov Med 10(52):247–254PubMed

19.

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070–1076PubMedCrossRef

20.

Zamboglou C, Messmer MB, Becker G, Momm F (2012) Stereotactic radiotherapy in the liver hilum: basis for future studies. Strahlenther Onkol 188(1):35–41PubMedCrossRef

21.

Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, Schwarz RE, Weatherall P, Chinsoo Cho L (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18(4):1081–1087PubMedCrossRef

22.

Ryu S, Jin R, Jin JY, Chen Q, Rock J, Anderson J, Movsas B (2008) Pain control by image-guided radiosurgery for solitary spinal metastasis. J Pain Symptom Manag 35(3):292–298CrossRef

23.

Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, Bepler G (2008) Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 26(7):1142–1147PubMedCrossRef

24.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMedCrossRef

25.

Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, Timmerman R (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75(3):677–682PubMedCrossRef

26.

Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7):1623–1631PubMedCrossRef

27.

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2(7 Suppl 3):S94–S100PubMedCrossRef

28.

Lo SS, Fakiris AJ, Teh BS, Cardenes HR, Henderson MA, Forquer JA, Papiez L, McGarry RC, Wang JZ, Li K, Mayr NA, Timmerman RD (2009) Stereotactic body radiation therapy for oligometastases. Expert Rev Anticancer Ther 9(5):621–635PubMedCrossRef

29.

Oshiro Y, Takeda Y, Hirano S, Ito H, Aruga T (2011) Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol 34(3):249–253PubMedCrossRef

30.

Mayr NA, Yuh WT, Taoka T, Wang JZ, Wu DH, Montebello JF, Meeks SL, Paulino AC, Magnotta VA, Adli M, Sorosky JI, Knopp MV, Buatti JM (2006) Serial therapy-induced changes in tumor shape in cervical cancer and their impact on assessing tumor volume and treatment response. AJR Am J Roentgenol 187(1):65–72PubMedCrossRef

31.

Force J, Rajan A, Dombi E, Steinberg SM, Giaccone G (2011) Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. J Thorac Oncol 6(7):1267–1273PubMedCrossRef

32.

Mantatzis M, Kakolyris S, Amarantidis K, Karayiannakis A, Prassopoulos P (2009) Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? Eur Radiol 19(7):1809–1816PubMedCrossRef

33.

Guiou M, Mayr NA, Kim EY, Williams T, Lo SS (2012) Stereotactic body radiotherapy for adrenal metastases from lung cancer. J Radiat Oncol doi:10.1007/s13566-012-0037-8

Title: Stereotactic body radiotherapy for adrenal metastases from lung cancer
Authors: Michael Guiou
Nina A. Mayr
Edward Y. Kim
Terence Williams
Simon S. Lo
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Journal of Radiation Oncology / Issue 2/2012
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-012-0037-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods and materials

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2012

A treatment planning method to avoid the larynx and eliminate the match-line in the treatment of head and neck cancer with intensity-modulated radiation therapy

Quality of life in patients with brain metastases using the EORTC QLQ-BN20 and QLQ-C30

Reirradiation of recurrent salivary gland malignancies with fractionated stereotactic body radiation therapy

Adjuvant chemotherapy in advanced nasopharyngeal carcinoma based on plasma EBV load

Post-thrombocythemic myeloid metaplasia with pleural involvement and the duration of response to external beam radiation therapy: a case report and literature review

Serum testosterone level after intensity-modulated radiotherapy in low-risk prostate cancer patients: does testicular dose correlate with testosterone level?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer